Contact and place of performance
Mike Erickson
Los Alamos, NM 87545
USA
Los Alamos National Laboratory scientists have developed high-affinity human antibodies that can quickly detect and potentially treat deadly, antibiotic-resistant plague infections, helping protect against both natural outbreaks and bioterror threats. The Challenge: Plague, caused by the bacterium Yersinia pestis , remains a serious threat—not just as a rare but deadly natural infection, but also as a potential...
View moreThis innovation enables more accurate diagnosis and opens the door to new treatments for plague, even in the face of antibiotic resistance or biological warfare scenarios.
Key Advantages:
Market Applications:
Development Status: TRL 5
US Patent No. 11,702,465
LA-UR-25-28651
LANL Tech Partnerships: Unlock the Innovative Potential
Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products.
LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact [email protected].
Note: This is not a call for external services for the development of this technology.
https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology
https://www.lanl.gov/engage/collaboration/feynman-center/tech-and-capability-search
Los Alamos National Laboratory (LANL), under the Department of Energy contractor Triad, is seeking commercial partners to license "PlagueGuard Antibodies," a technology designed to detect and treat infections caused by the *Yersinia pestis* bacterium. Scientists developed these high-affinity human antibodies to target the F1 antigen found in dangerous plague strains, addressing challenges related to antibiotic resistance and biowarfare threats. The innovation, which has reached Technology Readiness Level (TRL) 5 and is protected under U.S. Patent No. 11,702,465, offers picomolar binding affinities to minimize false positives and maintain effectiveness even when chemically modified for field diagnostics or therapeutic applications.
This special notice is classified under NAICS 325414 for Biological Product (except Diagnostic) Manufacturing and PSC 6505 for Drugs and Biologicals. The opportunity is intended for existing and start-up companies interested in exclusive or non-exclusive licensing agreements to transition these laboratory inventions into commercial innovations. Potential market applications include public health diagnostics, biodefense, radiopharmaceuticals, and targeted therapeutics. This notice serves as a technology licensing opportunity rather than a request for external development services.
The response deadline for this opportunity is October 10, 2025. Performances and development activities are centered in Los Alamos, New Mexico, and there is no set-aside designated for this notice. Inquiries and correspondence regarding solicitation number S-133813 are directed to the primary point of contact, Mike Erickson. Available metadata for the notice includes two image attachments providing technical summaries of the PlagueGuard technology.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.